Polymorphisms in XPG are considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We aimed to investigate the role of five potential SNPs of XPG gene on the response to platinum-based chemotherapy in advanced Chinese NSCLC patients. A total of 451 patients with newly diagnosed and histopathologically confirmed primary NSCLC were consecutively collected. XPG rs2296147, rs4150261, rs17655, rs1047768 and rs2094258 were genotyped by the Taqman real-time polymerase chain reaction (PCR). In our study, we found patients carrying rs1057768 TT genotype had a significantly lower treatment response when compared with the CC genotype (OR=0.38, 95% CI=0.18-0.78). Patients carrying rs1047768 TT genotype showed a significantly short median PFS (11.2 months) and OS (13.6 months) than CC genotype, and the hazard ratios (HR) for PFS and OS were 2.06 (1.01-4.50) and 2.29 (1.21-2.49), respectively. Moreover, we found a significant decreased risk of death from NSCLC among patients carrying the rs2296147 TT genotype when compared with the CC genotype, the HR (95% CI) for OS being 0.50 (0.27-0.95). In conclusion, our study found that polymorphisms in rs1047768 C/T and rs2296147 C/T are associated with response to platinum-based chemotherapy in advanced NSCLC, and XPG polymorphisms could be predictive of prognosis.
[1]Capital Med Univ, Beijing Chaoyang Hosp, Dept Radiotherapy, Changchun, Peoples R China.
[2]Jilin Univ, China Japan Union Hosp, Dept Dermatol, Changchun 130023, Peoples R China.
[3]Jilin Univ, China Japan Union Hosp, Dept Cardiac Surg, Changchun 130023, Peoples R China.
[4]Capital Med Univ, Beijing Shijitan Hosp, Dept Orthoped, Changchun, Peoples R China.
[5]Xinxiang Med Coll, Affiliated Hosp 1, Dept TB 4, Changchun, Peoples R China.
[6]Tumor Hosp Jilin Provice, Dept Oncol, Changchun, Peoples R China.
[7]Tumor Hosp Jilin Provice, Dept Surg Oncol, Changchun, Peoples R China.
(8.0+极速模式)